During the corresponding time, Bioxcel Therapeutics Inc recorded a revenue increase by 51.67 % year on year, sequentially revenue fell by -11.65 %. While revenue at the Bioxcel Therapeutics Inc 's corporate clients
BioXcel Therapeutics, an innovative biopharmaceutical company, is making significant strides in the treatment of two distinct health challenges: acute agitation associated with bipolar disorders and schizophrenia, as well as metastatic pancreatic ductal adenocarcinoma (PDAC). Recently, the company announced the initiation of its pivotal Phase 3 safety trial, SERENITY At-Home, investigating the use of BXCL501, a sublingual formulation of dexmedetomidine, in an at-home setting to treat agitation.The need for effective treatments for agitation, particularly in home environments, is underscored by the concerning statistic an estimated 23 million agitation episodes occur annually in these settings. The SERENITY...
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer s Dementia
Company plans to initiate trial following recent meeting with FDAIn a significant development aimed at addressing the growing challenges associated with agitation in patients suffering from Alzheimer s dementia, BioXcel Therapeutics has revealed its plan for the TRANQUILITY In-Care Pivotal Phase 3 Trial with the experimental drug BXCL501. The announcement comes on the heels of a recently held meeting between the company and the United States Food and Drug Administration (FDA).Alzheimer s dementia is a devastating neurodegenerative disease that not only a...
Sources:
Bioxcel Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Bioxcel Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Bioxcel Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
213.19 %